NCT07219654招募中2 期
A Phase 2, Double-blinded, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Allogeneic Dermal Fibroblasts (TPX-115) in Patients With Partial-thickness Rotator Cuff Tear
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 6
- 主要终点
- Change from baseline in Constant-Murley Score(CMS) at Week 24
研究概览
简要总结
The goal of this study is to evaluate the efficacy and safety of allogeneic dermal fibroblasts (TPX-115) compared to placebo in patients with Partial-Thickness Rotator Cuff Tear(PTRCT).
Primary endpoint is to evaluate the efficacy of TPX-115 compared to placebo, as measured by improvement in the Constant-Murley Score (CMS) in patients with PTRCT.
Secondary endpoints are:
- To evaluate functional (including shoulder pain) and structural improvements in the affected shoulder after administration of TPX-115 compared to placebo in patients with PTRCT
- To evaluate the safety and tolerability of TPX-115 in patients with PTRCT
- To assess the immunogenicity of TPX-115
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged >= 18 years.
- •Patients with PTRCT involving <= 50% of the tendon thickness based on depth of defect (or Grade I or II on Ellman classification) assessed by MRI within the last 3 months prior to screening and determined by the investigator.
- •Patients with clinical symptoms including but not limited to pain, muscle weakness, or limited active range of motion (ROM) of PTRCT persisting for more than 3 months despite conservation treatment.
- •Patients who report a usual pain level of >= 4 on visual analogue scale (VAS) at screening.
- •Patients who had, in the opinion of the investigator, at least 1 reasonable physical therapy course and no substantial response within 6 months prior to enrollment.
- •Patients who are willing to discontinue all pain medications on the shoulder (except rescue medication of < 3.25g acetaminophen per day) at least 72 hours prior to screening and throughout the duration of study.
- •Patients in general good health, with no concomitant conditions or taking treatments potentially representing confounding factors and interfering with the study treatment or study procedures and their results or putting the patient at a greater risk, as per the investigator's documented clinical judgment.
- •Patients who meet the following laboratory criteria, with results within 5% of the specified normal reference ranges:
- •Hemoglobin: 12 to 18 g/dL.
- •White Blood Cell (WBC) Count: 4.5 to 11.0 x 10^3/uL.
- •Patients with eGFR > 60 ml/min
- •Patients with ALT and AST < 3xUpper limit of normal
- •Patients who are willing and able to give written informed consent for participation in the study.
排除标准
- •Patients with full-thickness rotator cuff tear in the affected shoulder as assessed by MRI.
- •Patients with both partial- and full-thickness rotator cuff tear in the affected shoulder.
- •Patients who have experienced previous surgeries in the affected shoulder within 12 months prior to enrollment.
- •Patients who have received subacromial or intra-articular injection in the affected shoulder within 3 months prior to screening visit.
- •Patients who have a history of cell therapy or prolotherapy in the affected shoulder.
- •Patients who have received platelet-rich plasma (PRP) injection in the affected shoulder within 6 months prior to screening visit.
- •Patients who have received systemic immunosuppressive therapy within 4 weeks prior to screening visit.
- •Patients who have any of the following clinically significant diseases at screening or have medical history of past:
- •inflammatory joint disease (eg, septic arthritis, rheumatoid inflammation)
- •other shoulder disease, in the affected shoulder, that may cause shoulder pain or functional disorder (eg, arthritis, cervical spine disorders, subacromial pathological morphology leading to impingement syndrome)
- •autoimmune disease
- •active hepatitis B or C (except for simple carriers and hepatitis B patients with antiviral medications for 6 months before screening)
- •human immunodeficiency virus antibody-positive
- •history of systemic malignancy within the last 5 years
- •coagulopathy
- •genetic disorders affecting fibroblasts or collagen production (eg. achondroplasia, osteogenesis imperfecta)
- •other serious diseases (eg. neurological cardiovascular, renal or hepatic disease, uncontrolled diabetes, etc) that, inthe opinion of the investigator, might confound study results or pose additional risk to the patient by their participation in the study.
- •Female patients who are pregnant or breastfeeding.
- •Female patients planning pregnancy during the study period. Women of childbearing potential who do not agree to maintain contraception, or who do not agree to use the appropriate method of contraception (ie, double effective barrier contraception) during the study period.
- •Note: Suitable contraceptive methods are condom, sponge, gel, diaphragm for contraception, hormonal contraceptives, intrauterine device, etc. Periodic abstinence (eg, calendar method, ovulation method, symptom body temperature method, post-ovulation method) and restraint are not considered an accepted method of contraception. However, women unable to become pregnant due to menopause (at least 12 months since last menstrual period) can participate in the study with negative pregnancy test results.
- •Patients who have administered other IPs or devices within 4 weeks or 5 half-lives, whichever is greater, prior to the IP administration.
- •Patients whom the principal investigator considers inappropriate for the study due to any other reasons than those listed above.
研究组 & 干预措施
Cryopreserving hyaluronic acid medium
Experimental
干预措施: Cryopreserving hyaluronic acid medium (Other)
saline
Placebo Comparator
干预措施: Saline (Drug)
TPX-115 low dose
Experimental
干预措施: TPX-115 (Biological)
TPX-115 medium dose
Experimental
干预措施: TPX-115 (Biological)
TPX-115 high dose
Experimental
干预措施: TPX-115 (Biological)
结局指标
主要结局
Change from baseline in Constant-Murley Score(CMS) at Week 24
时间窗: Baseline, Week 24
The CMS is calculated from 0 (worst function) to 100 (best function) points
次要结局
- Change from baseline in Simple Shoulder Test at Weeks 4, 12, 24, and 52(Baseline, Week 4, Week 12, Week 24, Week 52)
- Change from baseline in tear size (mm) on MRI at Week 52(Baseline, Week 52)
- Change from baseline in tendon thickness (mm) on MRI at Week 52(Baseline, Week 52)
- Change from baseline in Constant-Murley Score(CMS) at Weeks 4, 12, and 52(Baseline, Week 4, Week 12, Week 52)
- Increase of at least 8 points from baseline in Constant-Murley Score(CMS) at Week 24(Baseline, Week 24)
- Change from baseline in Visual Analogue Scale(VAS) (0 to 10 cm) score for shoulder pain at Weeks 4, 12, 24, and 52(Baseline, Week 4, Week 12, Week 24, Week 52)
- Change from baseline in Range of Motion(ROM) in the affected shoulder at Weeks 4, 12, 24, and 52(Baseline, Week 4, Week 12, Week 24, Week 52)
- Change from baseline in American Shoulder and Elbow Surgeons(ASES) score at Weeks 4, 12, 24, and 52(Baseline, Week 4, Week 12, Week 24, Week 52)
- Change from baseline in Simple Shoulder Test at Weeks 4, 12, 24, and 52(Baseline, Week 4, Week 12, Week 24, Week 52)
- Change from baseline in tear size (mm) on MRI at Week 52(Baseline, Week 52)
- Change from baseline in tendon thickness (mm) on MRI at Week 52(Baseline, Week 52)
- Change from baseline in tear/footprint (%p) on MRI at Week 52(Baseline, Week 52)
- Change from baseline in tendinosis on MRI at Week 52(Baseline, Week 52)
研究者
研究点 (6)
Loading locations...
相似试验
招募中
2 期
Study of an Artificial Human Skin Medicine for Patients With Basal Cell Carcinoma Undergoing Reconstructive SurgeryBasal Cell CarcinomaNCT05234658Andalusian Network for Design and Translation of Advanced Therapies21
已完成
不适用
The Safety of a Novel Acellular Dermal Template as Treatment for Burns and ScarsFull Thickness Skin DefectsNCT02164760Association of Dutch Burn Centres13
Unknown
2 期
Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)Acute Pulmonary EmbolismNCT04110275Angde Biotech Pharmaceutical Co., Ltd.174
已完成
1 期
Treatment CLI Nonrevascularizable Lower Limb With Cell TherapyNonrevascularizable Critical Ischemia of the Lower LimbsNCT01824069Instituto de Investigación Hospital Universitario La Paz10
终止
1 期
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant DepressionTreatment Resistant DepressionNCT02675556Joshua M Hare1